Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

lief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers. Concomitant use of carboplatin and paclitaxel with sorafenib resulted in an increase in paclitaxel exposure and an increase in Nexavar exposure. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes. Nexavar exposure decreases when co-administered with oral neomycin. Effects of other antibiotics on Nexavar pharmacokinetics have not been studied.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.282
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
(Date:9/1/2015)... Taiwan,s GNT Biotech ... Taipei on  August 25 th ... a targeted drug delivery technology that uses nano-scale gold ... part of a joint press conference held by its ... showcasing GNT,s latest edible gold-based food and beverage partners, ...
(Date:9/1/2015)... DIEGO , Sept. 1, 2015 Agena Bioscience ... Shanghai , a commercial and financial hub ... growing number of genomic testing laboratories in mainland ... significant portion of Agena Bioscience,s global sales with almost sixty ... China will allow us to expand ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Agena Bioscience Opens Office in Shanghai, China 2
... 2011 /PRNewswire-Asia/ -- Golden Meditech Holdings Limited ("Golden ... healthcare enterprise, today announced that the Group has accumulated 754,791 ... ("CCBC," - CO.US) from the open market between December 2010 ... now owns 39.5% of the issued share capital of CCBC. ...
... June 23, 2011 Aoxing Pharmaceutical (NYSE Amex: ... focusing on research, development, manufacturing and distribution of narcotic ... unusual market activity in the Company,s common stock today, ... in accordance with its usual practice. In response, the ...
Cached Medicine Technology:Golden Meditech to Increase Stake in NYSE-listed Affiliate -- China Cord Blood Corporation to 39.5% 2Aoxing Pharmaceutical Company Has No Comment on Unusual Trading Activity 2
(Date:9/1/2015)... NY (PRWEB) , ... September 01, 2015 , ... From ... 86 children and teenagers, from ages 6-18. Calvary’s Camp Compass® has taken place at ... staff included 65 adult counselors, some of whom work for Calvary, and two junior ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... options to efficiently cure and prevent different malignancies. Some options for cancer ... pathophysiological properties due to which distinctive approach is necessary for effective treatment. ...
(Date:9/1/2015)... ... 2015 , ... Negative pressure wound therapy (NPWT) entails the ... exudates, fluid, and infectious materials to prepare the wound for healing and closure. ... canisters, etc.) is projected to expand continuously through 2021. , Rising patient and ...
(Date:9/1/2015)... Florida (PRWEB) , ... September ... ... of Professional Background Screeners (NAPBS®) has announced that Edge Information Management ... conducted by the Background Screening Credentialing Council (BSCC). , “Achieving and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, a leading global ... that it has hired Scott Sanderson, an experienced business development professional and former ... be responsible for establishing and managing new client relationships in the Southeast U.S. ...
Breaking Medicine News(10 mins):Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... July 31 With the world,s,attention focused on ... Miracles -- a 30-minute Sunday morning public affairs ... of real,patients -- will feature two of America,s ... Jenner. Sharing Miracles now shows on 158,television stations ...
... VANCOUVER, July 31 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced ... in Arlington Virginia. This Center is the Company,s first ... markets that CRH has targeted for,expansion. The opening of ... bringing the Company,s total number of Centers to 17., ...
... July 31 The American Association,of PPOs (AAPPO) ... course",for PPO executives on strategies to improve the ... AAPPO Adding Value Initiative will inform AAPPO,members and ... outcomes., (Logo: http://www.newscom.com/cgi-bin/prnh/20060126/CLTH062LOGO ), ...
... Policies Needed, WASHINGTON, July 31 As the ... convening of the,International AIDS Conference in Mexico City, the ... to announce on August 3rd,significantly higher HIV incidence numbers ... infections per year; the new number may be,more than ...
... number of unusual chromosomal changes, particularly structural changes that ... genes. These results were published today in the scientific ... in the structure of the genes in patients with ... number variants. Genetic diseases are caused by a large ...
... an increased risk of developing cardiovascular disease, particularly stroke ... Atherosclerosis , has now led to attempts to ... (hardening of the arteries) is an inflammatory disease in ... and become less elastic. It can cause blood clots ...
Cached Medicine News:Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 2Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 3Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 4Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 5Health News:'Sharing Miracles' Television Program to Feature Olympic Legends Mark Spitz and Bruce Jenner 6Health News:CRH Medical Corporation opens center in Virginia 2Health News:AAPPO Launches Short Course Conference Call Series on Value-added Strategies for PPOs 2Health News:Higher Number of HIV Infections Must Translate Into Leadership & Action by U.S. Government 2Health News:Unusual chromosomal changes increase the risk of schizophrenia 2Health News:New discovery may lead to immunization against cardiovascular disease 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: